WO2001002267A1 - Sachet d'emballage pour sparadrap - Google Patents
Sachet d'emballage pour sparadrap Download PDFInfo
- Publication number
- WO2001002267A1 WO2001002267A1 PCT/JP2000/004352 JP0004352W WO0102267A1 WO 2001002267 A1 WO2001002267 A1 WO 2001002267A1 JP 0004352 W JP0004352 W JP 0004352W WO 0102267 A1 WO0102267 A1 WO 0102267A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patch
- packaging bag
- member layer
- moisture
- water
- Prior art date
Links
- 238000004806 packaging method and process Methods 0.000 title claims abstract description 130
- 239000011505 plaster Substances 0.000 title abstract 7
- 239000005022 packaging material Substances 0.000 claims abstract description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229920001684 low density polyethylene Polymers 0.000 claims abstract description 33
- 239000004702 low-density polyethylene Substances 0.000 claims abstract description 33
- 230000035699 permeability Effects 0.000 claims abstract description 32
- 229920001903 high density polyethylene Polymers 0.000 claims abstract description 28
- 239000004700 high-density polyethylene Substances 0.000 claims abstract description 28
- 239000011256 inorganic filler Substances 0.000 claims abstract description 27
- 229910003475 inorganic filler Inorganic materials 0.000 claims abstract description 27
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 26
- 239000011888 foil Substances 0.000 claims abstract description 22
- 239000012298 atmosphere Substances 0.000 claims abstract description 6
- 238000007789 sealing Methods 0.000 claims description 33
- 229920005989 resin Polymers 0.000 claims description 26
- 239000011347 resin Substances 0.000 claims description 26
- 238000010521 absorption reaction Methods 0.000 claims description 20
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 19
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims description 11
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 230000005540 biological transmission Effects 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims 1
- 235000012745 brilliant blue FCF Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 46
- 239000003814 drug Substances 0.000 abstract description 46
- 229910052782 aluminium Inorganic materials 0.000 abstract description 17
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract description 17
- 239000000463 material Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 8
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 2
- 239000011358 absorbing material Substances 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 133
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 20
- 238000003860 storage Methods 0.000 description 20
- -1 polyethylene Polymers 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- 239000000853 adhesive Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 10
- 229920000298 Cellophane Polymers 0.000 description 9
- 230000001070 adhesive effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 229960005309 estradiol Drugs 0.000 description 7
- 229930182833 estradiol Natural products 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 6
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 5
- 229960001987 dantrolene Drugs 0.000 description 5
- 239000002274 desiccant Substances 0.000 description 5
- 239000012466 permeate Substances 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000013032 Hydrocarbon resin Substances 0.000 description 4
- 125000002723 alicyclic group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960001259 diclofenac Drugs 0.000 description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920006270 hydrocarbon resin Polymers 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- SQUNAWUMZGQQJD-UHFFFAOYSA-N 1-(4-ethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-one Chemical compound C1=CC(CC)=CC=C1C(=O)C(C)CN1CCCCC1 SQUNAWUMZGQQJD-UHFFFAOYSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960002565 eperisone Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920003051 synthetic elastomer Polymers 0.000 description 2
- 239000005061 synthetic rubber Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229920005992 thermoplastic resin Polymers 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- JOTMFOWEVMXFHO-UHFFFAOYSA-N 2-aminoethyl benzoate Chemical compound NCCOC(=O)C1=CC=CC=C1 JOTMFOWEVMXFHO-UHFFFAOYSA-N 0.000 description 1
- DIJNKKIYOHCAPO-UHFFFAOYSA-N 2-benzhydryloxy-n,n-diethylethanamine;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(OCCN(CC)CC)C1=CC=CC=C1 DIJNKKIYOHCAPO-UHFFFAOYSA-N 0.000 description 1
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- JQIYNMYZKRGDFK-RUFWAXPRSA-N Estradiol dipropionate Chemical compound C1CC2=CC(OC(=O)CC)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 JQIYNMYZKRGDFK-RUFWAXPRSA-N 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003920 antivertigo agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 229950005951 azasetron Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 1
- 229960003520 diphenidol Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 229950010215 estradiol dipropionate Drugs 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960003607 granisetron hydrochloride Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- QYZRTBKYBJRGJB-UHFFFAOYSA-N hydron;1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide;chloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3CC4CCCC(C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-UHFFFAOYSA-N 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940066974 medicated patch Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960000770 ondansetron hydrochloride Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940124535 smoking cessation aid Drugs 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B27/08—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/08—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/08—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
- B32B15/085—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/20—Layered products comprising a layer of metal comprising aluminium or copper
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/18—Layered products comprising a layer of synthetic resin characterised by the use of special additives
- B32B27/20—Layered products comprising a layer of synthetic resin characterised by the use of special additives using fillers, pigments, thixotroping agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/724—Permeability to gases, adsorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/726—Permeability to liquids, absorption
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2311/00—Metals, their alloys or their compounds
- B32B2311/24—Aluminium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2323/00—Polyalkenes
- B32B2323/04—Polyethylene
- B32B2323/043—HDPE, i.e. high density polyethylene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2323/00—Polyalkenes
- B32B2323/04—Polyethylene
- B32B2323/046—LDPE, i.e. low density polyethylene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2439/00—Containers; Receptacles
- B32B2439/80—Medical packaging
Definitions
- the present invention relates to a patch bag and a patch. Background art
- the drug which is a component of the patch, is released and penetrates into the blood through the skin, providing good biological effects to the human body. Is done.
- the drug in order to maintain the blood concentration of the drug stably and to increase the bioavailability, it is necessary to appropriately maintain the performance of releasing the drug from the patch. To this end, it is important that the drug release ability of the patch is not impaired between the time the patch is prepared and the time it is used.
- the drug is usually contained in the adhesive constituting the patch, but when the patch is left in the air, the solubility of the drug in the adhesive substance decreases, and the drug precipitates due to crystallization. There is a tendency. As a result, there has been a problem that the release rate of the drug from the adhesive layer is reduced.
- Japanese Patent Application Laid-Open No. 9-110 disclose techniques for controlling the humidity of a patch production environment, replacing with nitrogen, or packaging a desiccant together with the patch. ing. Further, Japanese Patent Application Laid-Open No. 5-39379 discloses a humidity control molded product containing magnesium sulfate. Disclosure of the invention
- the present inventors have conducted detailed studies on these conventional techniques, and as a result, have found that there are the following problems. That is, humidity control in the manufacturing environment To perform elemental substitution, the cost will increase due to the investment in manufacturing equipment and the increase in manufacturing processes and man-hours. Another problem is that using a desiccant package makes the product bulky. Further, there is a risk that the user may ingest the desiccant by mistake. Furthermore, in addition to such economical and handling problems, the conventional moisture-controllable molded articles tend to not always have a sufficient humidity-controlling effect on patches containing a drug.
- An object of the present invention is to provide a packaging bag for a patch that is excellent in economy and handleability. Another object of the present invention is to provide a packaged patch that can maintain good release of a drug from the patch.
- the present inventors have conducted intensive studies and found that the types of packaging members and their various properties influence the release performance of drugs from patches, and have reached the present invention. .
- the moisture-absorbing member layer made of the first resin containing 20 to 40% by weight of the inorganic filler is made of the second resin, and has a water permeability of 40 to 40%.
- the saturated moisture absorption capacity is located between a water-permeable member layer of 120 g / m 2 / day and a shielding member layer for blocking the transmission of moisture and light. It is made of a laminated packaging material of 2 to 30 gZm 2 under an atmosphere condition of a relative humidity of 75%, and is formed into a bag shape such that the water-permeable member layer is on the inside.
- the water vapor (water molecules) contained in the air inside the bag is gradually transmitted through the water-permeable member layer located on the innermost surface, thereby absorbing moisture. Reach the component layer. Some of these water molecules are absorbed by the inorganic filter contained in the moisture absorbing member layer. In addition, there are water molecules that permeate through the moisture absorbing member layer and diffuse to the outside. Among these water molecules, the water molecules are blocked by the shielding member layer, return to the moisture absorbing member layer, are absorbed by the inorganic filler, or are absorbed by the inorganic filler layer. In addition, there are many things that permeate the water-permeable member layer in the opposite direction and return to the internal space of the patch packaging bag again.
- the behavior of the water molecules is schematically described for convenience.In fact, the behavior of the water molecules is more complicated due to the diffusion of the water molecules and the adsorption / desorption equilibrium by an inorganic filler or the like. Presumed. However, the effect is not limited to this.
- the saturated moisture absorption capacity as a laminated packaging material is 25 ° C. It is kept at 2 to 30 g / m 2 under the condition of relative humidity of 75%.
- Saturated moisture absorption capacity of the laminated packaging material in the case of less than 2 gZm 2, the water that exists in the interior space of the patch packaging bag is not sufficiently absorbed in the laminated packaging material, the patch packaging bag When a patch is contained, the drug in the patch tends to precipitate.
- the saturated moisture absorption capacity of the laminated packaging material exceeds 30 gZm 2
- the moisture present in the internal space can be absorbed by the laminated packaging material to such an extent that the drying state becomes unsuitable for the patch.
- the adhesive component and the volatile component in the patch tend to evaporate and the adhesiveness tends to decrease. Therefore, according to the patch packaging bag of the present invention, the humidity of the internal space is favorably maintained in a range suitable for the patch. Therefore, when the patch is contained in the patch packaging bag, the deposition of the drug on the patch can be sufficiently prevented, and the adhesiveness of the patch is not impaired.
- the inorganic filler used as a moisture absorbing member is rich in hygroscopicity and excellent in dispersibility in resin, so that the amount (weight and volume) of the hygroscopic member can be reduced.
- the thickness of the laminated packaging material can be reduced.
- the first resin and the second resin may be the same or different.
- the first resin and the second resin are low-density polyethylene
- the shielding member layer is made of a metal foil and a high-density polyethylene layer.
- Low-density polyethylene hereinafter referred to as “LDPE”
- HDPE high-density polyethylene
- it is suitable for the moisture absorbing member layer and the water permeable member layer composed of LDPE.
- Moisture permeability is provided. As a result, the water permeability of the water-permeable member layer can be reliably maintained at a value within the above range.
- the water molecules that have passed through the water-permeable member layer and reached the moisture-absorbing member layer easily penetrate into the layer and are reliably absorbed by the inorganic filler.
- the shielding member layer is composed of a metal foil and an HDPE layer, the ability to block moisture and light is significantly improved.
- the thickness of the moisture-absorbing member layer is 20 to 40 zm
- the thickness of the water-permeable member layer is 5 to 15 // m
- the thickness of the high-density polyethylene layer constituting the shielding member layer is More preferably, the thickness of the metal foil constituting the shielding member layer is 5 to 15 zm.
- the patch packaging bag of the present invention is sealed by heat-sealing the laminated packaging material, and has a heat-sealing strength of 1.0 kg / 25 mn! It is preferable that it is 55.0 kg / 25 mm.
- the sealing of the patch packaging bag becomes extremely strong, and the permeation of moisture from the outside to the inside of the patch packaging bag is sufficiently prevented.
- the use of heat sealing makes the sealing extremely simple and strong. Become. If the heat seal strength is less than 1.0 kg / 25 mm, the sealed portion tends to peel off during storage due to the influence of the surrounding environment. On the other hand, if the heat seal strength exceeds 5.0 kg / 25 mm, a manufacturing error such as the sealing portion being cut during heat sealing may occur.
- the packaging patch according to the present invention comprises, in the patch packaging bag of the present invention, a support and a pressure-sensitive adhesive mainly composed of styrene-isoprene-styrene block copolymer laminated on the support.
- the total surface area inside the patch packaging bag is 1.2 to 10 times the total surface area of the patch.
- the patch packaging bag of the present invention can exhibit a humidity environment which is extremely suitable for storing such a patch having a pressure-sensitive adhesive. Therefore, the patch having the pressure-sensitive adhesive can be stored for a longer period and more favorably.
- the overall thickness of the laminated packaging material forming the packaging patch can be extremely thin, so that the thickness of the packaging patch can be approximately the same as the thickness of the patch. Therefore, the packaging patch is not bulky, and the storage density in an outer box or an outer bag and the storage density during storage can be increased, thereby saving space. Moreover, if the total surface area of the inside of the patch packaging bag is 1.2 to 10 times the effective area of the patch, the patch can be stored for a long time in a favorable humidity control environment. Further, the handling property when the patch is taken in and out of the patch packaging bag is improved.
- the “moisture permeability” refers to Japanese Industrial Standard JIS Z020
- LDPE low-density polyethylene
- HDPE high density polyethylene
- the “heat seal strength” in the present invention refers to a laminated packaging material having a width of 25 mm and a length of 80 mm based on the tensile strength and elongation specified in Japanese Industrial Standard JIS Z 0237 (1991.6). Is the measured value of the force when a tensile tester specified in Japanese Industrial Standards JISZ 023 7 (1991.6.2) was used as a test piece, with a test length of 50 mm and a pulling speed of 50 mm / min.
- the “effective area” of the patch in the present invention indicates an area of a site where a drug contained in the patch can be mainly released.
- a patch is formed by applying a pressure-sensitive adhesive containing a drug on a support, and the drug is mainly released from one side of the pressure-sensitive adhesive that is not in contact with the support. In this case, the area on one side is the “effective area”.
- FIG. 1 is a cross-sectional view schematically showing a preferred embodiment of a packaging patch according to the present invention. is there. BEST MODE FOR CARRYING OUT THE INVENTION
- FIG. 1 is a cross-sectional view schematically showing a preferred embodiment of a packaging patch according to the present invention.
- the packaging patch 10 has a configuration in which the patch 2 is disposed in a space 4 in a bag-shaped patch packaging bag 3 made of a laminated packaging material 1. The edges of the patch packaging bag 3 are sealed (sealed).
- the patch bag 3 and the patch 2 will be described in detail.
- the laminated packaging material 1 constituting the patch packaging bag 3 includes a water-permeable member layer 14 made of LDPE (second resin) and a moisture-absorbing member layer 13 made of LDPE (first resin) in which an inorganic filler is dispersed. And a shielding member layer composed of the HDPE layer 12 and the aluminum foil 11 are laminated in this order from the inside and adhered to each other.
- LDPE second resin
- LDPE first resin
- the thickness of each of the aluminum foil 11, HDPE layer 12, moisture-absorbing member layer 13, and water-permeable member layer 14 is preferably 5 to 15 juui 10 to 30 m, 20 to 40, respectively. 111, and 5 to 15 / m. Further, the thickness of the laminated packaging material 1 is preferably set to 40 to 100 zm.
- the laminated packaging material 1 has a saturated moisture absorption capacity of 2 to 30 g / m 2 under an atmosphere condition of a temperature of 25 ° (75% relative humidity.
- the saturated moisture absorption capacity is 2 g. If it is less than / m 2 , the moisture (water vapor, water molecules) contained in the air in the space 4 will not be sufficiently absorbed by the laminated packaging material 1, and the drug in the patch 2 tends to be easily precipitated.
- the water-permeable member layer 14 constituting the laminated packaging material 1 has a moisture permeability of 40 to 120 g / m 2 / day. Have been.
- the water-permeable member layer 14 is made of LDPE as described above. LDPE has a higher moisture permeability than a high-density resin body such as HDPE, and thus can reliably exhibit the moisture permeability in the above range.
- the layer thickness In order to achieve this moisture permeability in HDPE or the like, the layer thickness must be extremely thin. Then, the strength of the water-permeable member layer is reduced to such an extent that it cannot be put to practical use. On the other hand, according to the water-permeable member layer 14 of the present invention, since the layer thickness can be appropriately secured, the strength of the water-permeable member layer 14 can be made practically good.
- the water permeability of the water-permeable member layer 14 is less than 40 gZm 2 / day, the water contained in the air in the space 4 tends to not sufficiently reach the moisture-absorbing member layer 13.
- the moisture permeability exceeds 120 g / m 2 Z days, the space 4 tends to dry to an extent unsuitable for storing the patch 2. Therefore, in any case, it tends to be difficult to adjust and maintain the saturated moisture absorption capacity of the laminated packaging material 1 in the above range, that is, 2 to 30 gZm 2 .
- the content (ratio) of the inorganic filler dispersed in the moisture-absorbing member layer 13 constituting the laminated packaging material 1 is determined as follows. It is 20 to 40% by weight.
- the moisture absorbing member layer 13 employs LDPE as a matrix, and is excellent in dispersibility of the inorganic filler. This makes it possible to uniformly disperse the inorganic filler having such a content in the moisture absorbing member layer 13.
- LDPE has excellent moisture permeability
- moisture that has passed through the water-permeable member layer 14 easily permeates into the moisture-absorbing member layer 13.
- contact between the moisture and the inorganic filler in the moisture absorbing member layer 13 becomes frequent, and the moisture is easily absorbed by the inorganic filler.
- the content of the inorganic filler contained in the moisture-absorbing member layer 13 is less than 20% by weight, the moisture transmitted through the water-permeable member layer 14 is sufficiently absorbed by the moisture-absorbing member layer 13. There is no tendency.
- the content of the inorganic filler exceeds 40% by weight, the space 4 is easily dried to an unsuitable level for storing the patch 2, and the adhesive component and volatile component contained in the patch 2 absorb moisture. It is not preferable because there is a concern that it is adsorbed by the member layer 13. In any case, it tends to be difficult to adjust and maintain the saturated hygroscopicity of the laminated packaging material 1 within the above range. Further, when the content of the inorganic filler exceeds 40% by weight, it may be difficult to secure the sealing property when the laminated packaging material 1 is sealed by heat sealing.
- the type and form of the inorganic filler are not particularly limited.
- barium oxide, calcium chloride, magnesium sulfate, calcium oxide, calcium sulfate, lithium chloride, lithium perchlorate, alumina, silica gel, etc. are used. it can.
- magnesium sulfate from the viewpoint of having a humidity control property suitable for the patch 2 and excellent handleability.
- Magnesium sulfate is often used in the form of a hydrate, and the one having a small hydration number is more preferable because of the function of the patch packaging bag 3 that absorbs water.
- Patch 2 is obtained by laminating a pressure-sensitive adhesive 26 containing a drug on a support 25, and further attaching a liner 27.
- the material of the support 25 is not particularly limited, but is preferably a material having excellent flexibility while maintaining good drug release. Examples of such a material include films made of non-stretchable or stretchable polyester, polypropylene, polyethylene, vinyl acetate, vinyl chloride, and other resins; woven or non-woven fabrics made of those resin fibers; A composite of woven or non-woven fabric may be used.
- the pressure-sensitive adhesive 26 is composed of at least a base, a tackifier, and a softener, and their composition is not particularly limited. It is preferable that the adhesive agent has excellent adhesiveness to the skin, and the adhesive agent that has been conventionally used as a patch can be used.
- the base examples include natural rubber-based, synthetic rubber-based, acrylic-based, and silicon-based bases.
- synthetic rubbers polyisobutylene, polyisoprene, and the like may be used alone or in combination of two or more.
- SIS styrene-isoprenestyrene block copolymer
- examples of the tackifier include alicyclic saturated hydrocarbon resin, polyterpene resin, petroleum resin, rosin, hydrogenated rosin, hydrogenated rosin ester, and oil-soluble phenol resin. Of these, alicyclic saturated hydrocarbon resins and hydrogenated rosin esters are particularly preferably used.
- softening agent examples include those capable of plasticizing and softening the above-described base represented by SIS and the above-described tackifier represented by rosin ester derivative to maintain appropriate adhesion to skin. If so, there is no particular limitation. Specifically, for example, almond oil, olive oil, persimmon oil, persic oil, laccase oil, olefinic acid, liquid paraffin, and the like can be used. It is particularly preferable to use paraffin.
- the drug contained in the pressure-sensitive adhesive 26 is not particularly limited, and examples thereof include antiemetic agents such as granisetron hydrochloride, azasetron hydrochloride, ondansetron hydrochloride, and ramosetron hydrochloride, and frequent urinary remedies such as oxyptinin hydrochloride.
- antiemetic agents such as granisetron hydrochloride, azasetron hydrochloride, ondansetron hydrochloride, and ramosetron hydrochloride
- frequent urinary remedies such as oxyptinin hydrochloride.
- Ca antagonists such as difludipine, dizoldibin, dicardipine, ditredipine, corticosteroids such as hydrocortisone, prednisolone, clobesolate probionate, indomethacin, ketoprofen, flurbiprofen, and felbinac
- Antiphlogistic analgesics such as ketorolac diclofenacnatrime, hypnotic sedatives such as phenobarbi, triazolam, nitrazepam, lorazepam, tranquilizers such as flufenadine, diazepam, chlorpromazine, clonidine, clomiplasin hydrochloride, clonichlorine hydrochloride
- Antihypertensives such as sulphate, pindolol, propranolol, nitrendipine, and metoprolol; antihypertensive diuretics such as hide-mouth thi
- estradiol or a derivative thereof refers to natural estrogen, synthetic estrogen, and derivatives thereof, for example, estradiol, estradiol benzoate, estradiol dipropionate, estradiol valerate, ethinyl estradiol. And the like.
- the pressure-sensitive adhesive 26 that constitutes the patch 2 is included as a base.
- the SIS is included as a base.
- the SIS is included as a base.
- the component content of the pressure-sensitive adhesive 26 is preferably 10 to 74.1% by weight (particularly, when the base contains SIS and Z or polyisobutylene, the SIS is preferably 10 to 40% by weight, preferably 5 to 35% by weight, but the total of both does not exceed 74.1% by weight. It is suitable that the agent is preferably 10 to 55% by weight, the softener is preferably 15 to 30% by weight, and the drug is preferably 0.1 to 5% by weight.
- the preferable range of the above-mentioned base content can be determined by the preferable ranges of the content of the tackifier, the softener, and the drug.
- the thickness of the pressure-sensitive adhesive 26 is 10 ⁇ ! It is preferably from 300 to 300 m.
- the material of the liner 27 is not particularly limited, and a silicon or fluorine-treated polyester film, paper, or the like can be used.
- Examples of a method for producing the patch 2 having such a configuration include: (1) After heating and dissolving the base component, adding a drug, plastering the support, covering with a liner, and cutting the product into a desired shape. Or (2) After heating and dissolving the base component, add the drug, and once apply it to a peeled film, transfer it to an appropriate support and press-bond it to produce a product. Can also.
- the method for producing the packaging patch 10 is not particularly limited, and examples thereof include the following method. That is, the sheet-like (film-like) laminated packaging material 1 is overlapped with the water-permeable member layer 14 side inside so that the patch 2 is sandwiched from both sides, and the normal sealer is placed at a desired position.
- a method of sealing by applying heat (so-called heat sealing) and cutting out the outer periphery of the sealed portion can be used.
- the heat sealing strength at this time is preferably 1.0 kg / 25 mm to 5. Ok g / 25 mm. If the heat seal strength is less than 1.0 kgZ25 mm, the seal will tend to peel off due to the surrounding environment during storage. On the other hand, when the heat seal strength exceeds 5.0 kg / 25 mm, there is a possibility that a manufacturing error such as the sealing portion being cut during heat sealing may occur.
- the total surface area inside the packaging bag 3 for the patch is 1.2 to 10 times the effective area of the patch 2. If this ratio is less than 1.2, the content of the inorganic filler is insufficient, and the space 4 in the packaging patch 10 tends to be insufficient to keep the patch in a favorable environment for a long period of time. Moreover, in this case, it is difficult to put patch 2 in and out of patch bag 3 for patch.
- this ratio exceeds 10 times, the inside of the space 4 tends to be in an excessively dry state, and the adhesive component, the volatile component, and the like of the patch 2 tend to be adsorbed to the patch packaging bag 3.
- the above range of the ratio is particularly suitable when the adhesive 2 having the above-mentioned pressure-sensitive adhesive 26 mainly composed of SIS is used.
- the shielding member layer constituting the laminated packaging material 1 is composed of the HDPE layer 12 and the aluminum foil 11, but the laminated packaging material 1 blocks moisture and light.
- Other members may be used as long as the members can be sealed, and a member having a heat-sealable member such as the HDPE layer 12 is preferable.
- Such other members include those obtained by laminating one or more of heat-sealable polyethylene, polypropylene, and ethylene vinyl acetate on a metal foil other than aluminum. Further, it is preferable that polyester, cellophane, paper, or the like be laminated on the outer side of the aluminum foil 11 or other metal LU in appearance.
- the patch packaging bag 3 may be formed of a member that is transparent to that wavelength of light. From the viewpoint of stably holding the patch component, those having a property of blocking near-infrared light, infrared light and ultraviolet light are preferred.
- LDPE is used as the resin constituting the moisture absorbing member layer 13, other resins may be used.
- the resin has appropriate moisture permeability, is a heat sealable resin, and It is preferable that the inorganic filler has excellent dispersibility. Examples of such other trees include polypropylene, ethylene vinyl acetate, and the like.
- the water molecules present in the space 4 allow the water-permeable member located on the innermost surface of the packaging bag 3 to be patched. It gradually penetrates the layer 14 and reaches the moisture absorbing member layer 13. Some of these water molecules are absorbed by the inorganic filter contained in the moisture absorbing member layer 13.
- water molecules permeate the moisture-absorbing member layer 13 and diffuse to the HDPE layer 12 side, and most of the water molecules are formed by the HDPE layer 12 and the aluminum foil 11. Is returned to the moisture absorbing member layer 13 and absorbed by the inorganic filler. Alternatively, some of such water molecules may permeate through the moisture absorbing member layer 13 and the water permeable member layer 14 in the opposite directions and return to the space 4 again. As a result, the humidity or water vapor pressure in the space 4 approaches an equilibrium value governed by the volume of the space 4, the water permeability of the water-permeable member layer 14, and the like.
- the saturated moisture-absorbing ability of the laminated packaging material 1 is as follows. It is well maintained at 2-30 g / m 2 under the atmosphere condition of 5 ° C and 75% relative humidity. Therefore, since the saturated moisture absorption capacity of the laminated packaging material 1 is set to a value within such a range, the humidity in the space 4 is favorably maintained in a range suitable for the patch 2, and is included in the patch 2. In addition, it is possible to sufficiently prevent the precipitation of the drug, and the adhesiveness of the patch is not impaired. Therefore, the effect of water on the drug in Patch 2 can be sufficiently reduced, and Patch 2 can be kept stable for a long period of time.
- this effect can be achieved by controlling the humidity of the manufacturing environment, replacing nitrogen, or applying a desiccant. Since this is achieved without packaging together with the agent 2, it is possible to sufficiently improve the economy and handling. In addition, since it is not necessary to use a desiccant, the bulk of the patch 10 can be eliminated and the size of the patch 10 can be reduced. Therefore, the density of the packaged patch 10 during storage can be increased, and the storage space can be reduced.
- the inorganic filler which is highly absorbent, is used as the moisture absorbing member. Since the inorganic filler is excellent in dispersibility in resin, the amount (weight, volume) of the moisture absorbing member is reduced, and the laminate is laminated. The thickness of the packaging material 1 can be reduced. Therefore, the size of the packaging patch 10 can be further reduced.
- the first resin and the second resin are made of LDPE which is relatively excellent in moisture permeability
- the moisture absorbing member layer 13 and the water permeable member layer 14 made of LDPE are used. Moderate moisture permeability. Therefore, the water permeability of the water-permeable member layer 14 can be reliably set to a value within the above range. Therefore, the water molecules that have passed through the water-permeable member layer 14 and reached the moisture-absorbing member layer 13 easily enter the moisture-absorbing member layer 13 and are surely absorbed by the inorganic filler.
- the shield member layer is formed of the aluminum foil 11 and the HDPE layer 12, the property of blocking moisture and light can be improved.
- the thickness of the moisture absorbing member layer 13 is 20 to 40 m
- the thickness of the water permeable member layer 14 is 5 to 15 zm
- the thickness of the HDPE layer 12 constituting the shielding member layer is 10 to 30. zm
- the thickness of the aluminum foil 11 constituting the shielding member layer is 5 to 15 zm, so that the laminated package material 1 reliably and satisfactorily achieves the saturated moisture absorbing ability in the above-described range.
- the overall thickness of the laminated packaging material 1 is about 100 zm or less, it is possible to prevent bulkiness even when the patch is stored. Therefore, the packing density of the packaging patch 10 in the outer box or the outer bag and the storage density during storage can be increased, and the space can be further reduced.
- the heat sealing strength of the laminated packaging material 1 is 1.0 kg / 25 mm to 5.
- each layer of the laminated packaging material 1 constituting the patch packaging bag 3 is mainly formed of a thermoplastic resin, the use of heat sealing makes the sealing extremely simple and strong.
- the heat seal strength is 1.0 kg / 25 mm or more, it is possible to prevent the seal portion from easily peeling off during storage.
- the heat sealing strength is 5.0 kg / 25 mm or less, the occurrence of manufacturing errors during heat sealing such as cutting of the sealing portion can be reduced significantly.
- the patch packaging bag 3 can satisfactorily develop the humidity suitable for the patch 2 including the pressure-sensitive adhesive 26 mainly composed of SIS, the patch 2 is made of such a pressure-sensitive adhesive 26. If it does, good retention is possible for a longer period. Furthermore, if the total surface area of the inside of the patch packaging bag 3 is 1.2 to 10 times the effective area of the patch 2, the patch 2 can be stored for a long time in a favorable humidity control environment. Moreover, the handling property when the patch 2 is taken in and out of the patch packaging bag 3 can be improved.
- Permeability member layer LDPE (thickness 10 m, moisture permeability 60 g / m 2 / day) • moisture absorbing member layer: LDPE (thickness 30 ⁇ M, containing 30% by weight of magnesium sulfate) • shielding member layer: HDPE (Thickness: 20 ⁇ m), aluminum foil (thickness: 9 m) The saturated moisture absorption capacity of this laminated packaging material was measured and found to be 23 g / m 2 . Next, the laminated packaging material was formed into a bag shape by heat sealing so that the water-permeable member layer was on the inside. Thus, a patch packaging bag was obtained.
- Water-permeable member layer LDPE (thickness 5 / im, moisture permeability 120 g / m 2 Z days)-Hygroscopic member layer: LDPE (thickness 30 ⁇ m, containing magnesium sulfate 38% by weight) 'Shielding member layer: HDPE (thickness: 30 m), aluminum foil (thickness: 15 ⁇ m)
- the saturated moisture absorption capacity of this laminated packaging material was measured and found to be 30 g / m 2 .
- the laminated packaging material was formed into a bag shape by heat sealing so that the water-permeable member layer was on the inside, to obtain a patch packaging bag.
- LDPE LDPE (15 m thick, moisture permeability 40 gZm 2 / day) • Hygroscopic member layer: LDPE (30 m thick, containing 20% by weight of magnesium sulfate)-Shielding member layer: HDPE (thickness) 10 ⁇ m), aluminum foil (thickness 5 ⁇ m) When the saturated moisture absorption capacity of this laminated packaging material was measured, it was 2 gZm 2 . Next, this laminated packaging material was formed into a bag shape with a heat seal so that the water-permeable member layer was on the inside, to obtain a patch packaging bag.
- Water-permeable member layer LDPE (thickness 10 ⁇ m, moisture permeability 60 g / m 2 days)
- LDPE low density polyethylene
- HDPE high density polyethylene
- Polyethylene glycol acrylate 0.1% by weight
- LDPE thickness 10 ⁇ m, moisture permeability 60 g / m 2 / day
- this laminated packaging material When the saturated moisture absorbing ability of this laminated packaging material was measured, it was 0.8 gZm 2 . Next, this laminated packaging material was formed into a bag shape by heat sealing so that the water-permeable member layer was on the inside, to obtain a packaging bag for patches.
- 'Shielding member layer HDPE (thickness 20 zm), aluminum foil (thickness 9 ⁇ M) was measured saturation moisture absorption capability of the laminated packaging material was 1. 5 g Roh m 2. Next, this laminated packaging material was formed into a bag shape by heat sealing so that the water-permeable member layer was on the inside, to obtain a packaging bag for patches.
- a packaging bag for patches was prepared according to the present invention as shown in (1) below, and the total surface area inside the packaging bag for patches was reduced as shown in (2) below.
- a patch was prepared which was 1.1 times the effective area of the patch.
- Water-permeable member layer LDPE (thickness 15 m, moisture permeability 40 g / m 2 Z days)
- LDPE low density polyethylene
- HDPE thin film polyethylene
- aluminum foil thin film
- the laminated packaging material was formed into a bag shape by heat sealing so that the water-permeable member layer was on the inside, to obtain a patch packaging bag.
- Test sample Each patch immediately after preparation in Examples 1 to 6 and Comparative examples 1 to 3 (that is, no storage period), and each patch in Examples 1 to 6 and Comparative examples 1 to 3
- the packaged patch is stored in a thermo-hygrostat at a temperature of 40 ° C and a relative humidity of 75%, and after one month, three months and six months, the patch removed from the patch packaging bag is used as a test sample. did.
- Test Method The support side of the test sample was fixed to the center of the rotating cylinder using a silicone adhesive, and the liner was peeled off. Next, 900 ml of degassed water as a test solution is placed in a container, the water temperature (liquid temperature) is maintained at 32 ⁇ 0.5 ° C, and the distance between the lower end of the rotating cylinder and the inner surface of the container bottom wall is 12 ⁇ . The rotating cylinder was immersed in the test solution so as to be 2 mm, and the supporting part of the rotating cylinder was fixed. Next, the drug was eluted into the test solution while rotating the rotary cylinder at a rotation speed of 50 times per minute.
- test solution was sampled at the height where the patch was fixed and at a position at least 10 mm away from the side wall of the container, and used as a sample solution. After the sample solution was collected, 10 ml of water preliminarily heated to 32 ⁇ 0.5 ° C was immediately added to supplement the test solution.
- the liquid chromatographic method was used to detect the drug in the sample solution and the standard solution (50/1), and the peak area (intensity) in each chart was compared to determine the drug concentration in the sample solution. Based on the dilution of the solution and the volume of the lysate, The amount of drug released from the patch of the sample was determined. Based on the result, the following formula (5):
- the drug release rate (%) was calculated from the relationship expressed as Here, in the formula, Ri is the drug for the sample i (the subscript i indicates that the storage period of the patch in the patch packaging bag is one month, three months, or six months). Indicates the release rate (%) of the sample, ni indicates the amount of drug released from the sample sample i (mg), and ⁇ indicates the amount of drug (mg) in the sample sample for a storage period of 0 months. Table 1 summarizes the release rates calculated in this way.
- the packaging bags for patch (100 each) were prepared at a temperature of 60 ° C. It was left for 1 to 12 months under an atmosphere condition of a relative humidity of 75%.
- the effect of moisture on the drug in the patch is reduced.
- the patch is sufficiently reduced, and the patch can be stably held for a long period of time, and a patch packaging bag excellent in economy and handleability can be obtained.
- a patch packaging bag excellent in economy and handleability can be obtained.
- by using the package for a patch it is possible to realize a packaged patch that can maintain good release of a drug from the patch.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/019,400 US6991095B1 (en) | 1999-07-02 | 2000-06-30 | Packaging bag for plaster and packaged plaster |
BR0012123-1A BR0012123A (pt) | 1999-07-02 | 2000-06-30 | Embalagem para emplastro medicinal e emplastro medicinal embalado |
EP00942421.9A EP1209097B1 (en) | 1999-07-02 | 2000-06-30 | Packaging bag for plaster and packaged plaster |
AU57074/00A AU5707400A (en) | 1999-07-02 | 2000-06-30 | Packaging bag for plaster and packaged plaster |
CA002376291A CA2376291A1 (en) | 1999-07-02 | 2000-06-30 | Patch package and packaged patch |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11189204A JP2001009985A (ja) | 1999-07-02 | 1999-07-02 | 貼付剤用包装袋及び包装貼付剤 |
JP11/189204 | 1999-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001002267A1 true WO2001002267A1 (fr) | 2001-01-11 |
Family
ID=16237283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/004352 WO2001002267A1 (fr) | 1999-07-02 | 2000-06-30 | Sachet d'emballage pour sparadrap |
Country Status (7)
Country | Link |
---|---|
US (1) | US6991095B1 (ja) |
EP (1) | EP1209097B1 (ja) |
JP (1) | JP2001009985A (ja) |
AU (1) | AU5707400A (ja) |
BR (1) | BR0012123A (ja) |
CA (1) | CA2376291A1 (ja) |
WO (1) | WO2001002267A1 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4865958B2 (ja) * | 2001-05-23 | 2012-02-01 | 株式会社トクホン | 鎮痛抗炎症局所作用型の貼付剤 |
US8110260B2 (en) * | 2007-02-02 | 2012-02-07 | Rick Merical | Containers intended for moisture-sensitive products |
US7871558B2 (en) * | 2002-06-20 | 2011-01-18 | Alcan Global Pharmaceutical Packaging, Inc. | Containers intended for moisture-sensitive products |
US8003179B2 (en) | 2002-06-20 | 2011-08-23 | Alcan Packaging Flexible France | Films having a desiccant material incorporated therein and methods of use and manufacture |
US7785622B2 (en) * | 2002-09-13 | 2010-08-31 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch for fentanyl administration |
JP2004352297A (ja) * | 2003-05-29 | 2004-12-16 | Hisamitsu Pharmaceut Co Inc | 横型包装用袋体 |
DE10350030A1 (de) * | 2003-10-27 | 2005-06-02 | Hilti Ag | Lager- und Transporteinrichtung für Dosierköpfe |
JP4989892B2 (ja) * | 2004-01-30 | 2012-08-01 | 久光製薬株式会社 | 貼付剤入り包装袋 |
JP2007530378A (ja) † | 2004-03-26 | 2007-11-01 | シーエスピー テクノロジーズ,インコーポレイティド | フレキシブルパッケージに接着された活性フィルム及びその方法 |
JP4884711B2 (ja) * | 2004-06-29 | 2012-02-29 | 久光製薬株式会社 | 包装袋 |
JP4774724B2 (ja) * | 2004-11-18 | 2011-09-14 | 凸版印刷株式会社 | 包装体 |
CN101166531A (zh) * | 2005-04-20 | 2008-04-23 | 日绊株式会社 | 经皮吸收制剂 |
JP2006346888A (ja) * | 2005-06-13 | 2006-12-28 | Kyodo Printing Co Ltd | 選択吸湿フィルム及び多層フィルム |
DE102006011338A1 (de) * | 2006-03-09 | 2007-09-13 | Grünenthal GmbH | Pflasterverpackung |
MX2008014314A (es) * | 2006-05-08 | 2009-02-10 | Sarmas Group Llc | Empaquetamiento de productos y metodos para hacerlo. |
US20090324142A1 (en) * | 2006-06-16 | 2009-12-31 | Toyo Aluminium Kabushiki Kaisha | Packaging material and bag for packaging of medicinal product |
JP5075378B2 (ja) * | 2006-09-08 | 2012-11-21 | 久光製薬株式会社 | 貼付剤製品 |
JP2008094426A (ja) * | 2006-10-11 | 2008-04-24 | Teikoku Seiyaku Co Ltd | 包装袋 |
JP5059584B2 (ja) * | 2007-01-11 | 2012-10-24 | 日東電工株式会社 | 貼付剤包装構造 |
EP2070556B1 (en) | 2007-12-14 | 2016-04-06 | Nitto Denko Corporation | Patch package structure |
KR101539771B1 (ko) * | 2007-12-14 | 2015-07-27 | 닛토덴코 가부시키가이샤 | 패치 포장 구조체 |
CH700645A2 (de) * | 2009-03-20 | 2010-09-30 | Alcan Tech & Man Ltd | Deckfolie als Durchdrückfolie für eine Blisterpackung. |
CN102361639A (zh) * | 2009-04-24 | 2012-02-22 | 久光制药株式会社 | 内包贴附剂的包装袋、及贴附剂的保存方法 |
DE102009032744A1 (de) * | 2009-07-11 | 2011-01-13 | Thinxxs Microtechnology Ag | Fluidspeicher |
US8973748B2 (en) * | 2011-01-19 | 2015-03-10 | Boston Scientific Scime, Inc. | Medical device packaging and methods for preparing and packaging medical devices |
US9096368B2 (en) * | 2011-01-19 | 2015-08-04 | Boston Scientific Scimed, Inc. | Medical device packaging and methods for preparing and packaging medical devices |
US8900626B2 (en) * | 2011-06-20 | 2014-12-02 | Senju Usa, Inc. | Transdermal drug delivery system and method of using the same |
JP2013216343A (ja) * | 2012-04-06 | 2013-10-24 | Nitto Denko Corp | 貼付剤の包装構造および貼付剤の包装方法 |
CN104476849A (zh) * | 2014-11-25 | 2015-04-01 | 苏州九鼎珍珠棉有限公司 | 一种ldpe高发泡复合镀铝膜及其制备方法 |
JP6653967B2 (ja) * | 2016-05-27 | 2020-02-26 | 株式会社吉野工業所 | 調湿容器 |
US20180319131A1 (en) * | 2017-05-03 | 2018-11-08 | Switch Materials Inc. | Packaged film assembly for lamination between substrates |
JP7320938B2 (ja) | 2018-11-29 | 2023-08-04 | 共同印刷株式会社 | 低吸着性吸湿フィルム |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04189779A (ja) * | 1990-11-22 | 1992-07-08 | Marutani Kakoki Kk | 軽包装用シート材及びこれを用いた軽包装袋 |
JPH06209981A (ja) * | 1993-01-19 | 1994-08-02 | Terumo Corp | 医療容器用基材 |
JPH0728550U (ja) * | 1993-11-08 | 1995-05-30 | 積水化学工業株式会社 | 貼付剤用包装袋 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1239122A (en) * | 1984-02-09 | 1988-07-12 | Toshio Komatsu | Package containing quality-retaining agent |
JPS62165264A (ja) | 1986-01-17 | 1987-07-21 | Toshiba Corp | プラント機器保守診断作業支援装置 |
US4861632A (en) * | 1988-04-19 | 1989-08-29 | Caggiano Michael A | Laminated bag |
JPH0753222B2 (ja) | 1989-05-23 | 1995-06-07 | 富田製薬株式会社 | 乾燥剤組成物 |
JPH0539379A (ja) * | 1991-08-08 | 1993-02-19 | Sasaki Kagaku Yakuhin Kk | 調湿性組成物及び調湿性成形品 |
JPH0728550A (ja) | 1993-07-08 | 1995-01-31 | Fujitsu Ten Ltd | 計数装置 |
US5698217A (en) * | 1995-05-31 | 1997-12-16 | Minnesota Mining And Manufacturing Company | Transdermal drug delivery device containing a desiccant |
JP2774257B2 (ja) | 1995-07-25 | 1998-07-09 | 帝三製薬株式会社 | 安定なエストラジオール含有貼付剤の製造法 |
JP3525272B2 (ja) | 1995-11-06 | 2004-05-10 | 久光製薬株式会社 | 皮膚貼付用シート |
JPH10167284A (ja) | 1996-12-12 | 1998-06-23 | Dainippon Printing Co Ltd | 包装袋 |
-
1999
- 1999-07-02 JP JP11189204A patent/JP2001009985A/ja active Pending
-
2000
- 2000-06-30 AU AU57074/00A patent/AU5707400A/en not_active Abandoned
- 2000-06-30 EP EP00942421.9A patent/EP1209097B1/en not_active Expired - Lifetime
- 2000-06-30 WO PCT/JP2000/004352 patent/WO2001002267A1/ja active Application Filing
- 2000-06-30 CA CA002376291A patent/CA2376291A1/en not_active Abandoned
- 2000-06-30 US US10/019,400 patent/US6991095B1/en not_active Expired - Lifetime
- 2000-06-30 BR BR0012123-1A patent/BR0012123A/pt not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04189779A (ja) * | 1990-11-22 | 1992-07-08 | Marutani Kakoki Kk | 軽包装用シート材及びこれを用いた軽包装袋 |
JPH06209981A (ja) * | 1993-01-19 | 1994-08-02 | Terumo Corp | 医療容器用基材 |
JPH0728550U (ja) * | 1993-11-08 | 1995-05-30 | 積水化学工業株式会社 | 貼付剤用包装袋 |
Also Published As
Publication number | Publication date |
---|---|
EP1209097A1 (en) | 2002-05-29 |
EP1209097A4 (en) | 2009-11-11 |
AU5707400A (en) | 2001-01-22 |
EP1209097B1 (en) | 2016-04-27 |
BR0012123A (pt) | 2002-06-11 |
JP2001009985A (ja) | 2001-01-16 |
CA2376291A1 (en) | 2001-01-11 |
US6991095B1 (en) | 2006-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001002267A1 (fr) | Sachet d'emballage pour sparadrap | |
JP5329197B2 (ja) | 貼付剤包装構造 | |
US20070158227A1 (en) | Plaster enclosing packaging bag | |
JP5933974B2 (ja) | 貼付剤入り包装袋、及び貼付剤の保存方法 | |
JP4139689B2 (ja) | 経皮薬物送達システムのための包装システム | |
CA2646621C (en) | Patch package structure | |
WO2005072675A1 (ja) | 貼付剤入り包装袋及び薬物移行抑制方法 | |
AU2008221861B2 (en) | Device for the transdermal administration of bisoprolol | |
WO2017094491A1 (ja) | 貼付剤の包装構造 | |
JPH09299445A (ja) | 薬物含有貼付剤用包装体 | |
FI118720B (fi) | Estradioli-TTS, jossa on vettä sitovia lisäaineita | |
JP2008061862A (ja) | 貼付剤製品 | |
WO2017170933A1 (ja) | 貼付剤製品 | |
JP3098095B2 (ja) | 透湿性支持体を用いた貼付剤 | |
JP2018177758A (ja) | リバスチグミン含有経皮吸収製剤 | |
CN116887796A (zh) | 含有双氯芬酸的贴附剂包装制品及双氯芬酸钠的稳定化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN ID KR NO SG US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10019400 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2376291 Country of ref document: CA Ref document number: 2376291 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000942421 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200200130 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 2000942421 Country of ref document: EP |